Expanding diagnostics business: SCHOTT signs agreement to acquire Applied Microarrays Inc.

 

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI aims to further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October.

Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection.

“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalisation and deposition for both glass and polymer products,” said Greg Wolters, head of SCHOTT MINIFAB.

“We are joining SCHOTT at a time when the market continues to steer toward point-of-care diagnostics,” adds Alastair Malcolm, CEO of AMI. “Our joint knowledge and technical capability allows us to offer a more holistic approach while shortening the time to market for customers.”

AMI will soon be moving to a larger facility in the Phoenix, Arizona area. Its new location will greatly increase SCHOTT’s manufacturing footprint in the United States to serve its global customer base.

Caption: SCHOTT MINIFAB has extensive bioscience capabilities across Australia, Europe and now in the USA (photo: SCHOTT MINIFAB)